about
A Ca(2+)-activated NADPH oxidase in testis, spleen, and lymph nodesCancer cell-autonomous TRAIL-R signaling promotes KRAS-driven cancer progression, invasion, and metastasisHigh circulating activin A level is associated with tumor progression and predicts poor prognosis in lung adenocarcinoma.From Bench to Bedside: Attempt to Evaluate Repositioning of Drugs in the Treatment of Metastatic Small Cell Lung Cancer (SCLC)Invasion from a cell aggregate--the roles of active cell motion and mechanical equilibrium.Differential effects of polymorphic alleles of FGF receptor 4 on colon cancer growth and metastasisUltrastructural characterization of the optic pathway in a mouse model of neurofibromatosis-1 optic gliomaEncephalitis and GABAB receptor antibodies: novel findings in a new case series of 20 patientsOncolytic influenza A virus expressing interleukin-15 decreases tumor growth in vivo.Erythropoietin receptor expression is a potential prognostic factor in human lung adenocarcinoma.Localization of sunitinib, its metabolites and its target receptors in tumour-bearing mice: a MALDI-MS imaging study.Prenylation inhibition-induced cell death in melanoma: reduced sensitivity in BRAF mutant/PTEN wild-type melanoma cellsMononuclear cell secretome protects from experimental autoimmune myocarditisStromal expression of heat-shock protein 27 is associated with worse clinical outcome in patients with colorectal cancer lung metastasesKi67 index is an independent prognostic factor in epithelioid but not in non-epithelioid malignant pleural mesothelioma: a multicenter study.Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis.A comparison of sample preparation strategies for biological tissues and subsequent trace element analysis using LA-ICP-MS.Limited Tumor Tissue Drug Penetration Contributes to Primary Resistance against Angiogenesis InhibitorsThe neurobiology of neurooncology.Optic nerve dysfunction in a mouse model of neurofibromatosis-1 optic glioma.KRAS-mutation incidence and prognostic value are metastatic site-specific in lung adenocarcinoma: poor prognosis in patients with KRAS mutation and bone metastasis.Circulating fibrinogen is a prognostic and predictive biomarker in malignant pleural mesotheliomaVessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models.KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.KRAS mutation testing of colorectal cancer for anti-EGFR therapy: dogmas versus evidence.Lung cancer in never smokers.The role of microRNAs in the diagnosis and treatment of malignant pleural mesothelioma--a short review.Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro.RIG-I inhibits the MAPK-dependent proliferation of BRAF mutant melanoma cells via MKP-1.Epigenetic down-regulation of integrin α7 increases migratory potential and confers poor prognosis in malignant pleural mesothelioma.Fibroblast growth factor receptor inhibition is active against mesothelioma and synergizes with radio- and chemotherapy.Expression of microRNA-21 in non-small cell lung cancer tissue increases with disease progression and is likely caused by growth conditional changes during malignant transformation.IL-24 sensitizes tumor cells to TLR3-mediated apoptosisIrradiation and Taxol treatment result in non-monotonous, dose-dependent changes in the motility of glioblastoma cells.BARD1 serum autoantibodies for the detection of lung cancer.Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma.Detection and measurement of neurofibromatosis-1 mouse optic glioma in vivoIntrathoracic solitary fibrous tumor - an international multicenter study on clinical outcome and novel circulating biomarkers.Antimicrobial peptides are highly abundant and active in postoperative pleural drainage fluids.Targeting an Oncolytic Influenza A Virus to Tumor Tissue by Elastase.
P50
Q24291514-BC0FDC92-D489-498C-A061-CEE9AFBEE745Q24336049-39635989-52D7-4A1D-9D34-5EB4024085B4Q27853357-6EAC9D45-5E14-45C9-B666-28536E27C3F1Q28552102-2E6069AA-03BA-4D18-A38B-D43102F440EDQ30586633-5E427F2C-4DA4-4DC1-B3C6-8BC3D6D99419Q33757125-B5A870AC-2EAA-4D48-BEA0-503430E2CABAQ34079603-8A000797-48C5-4798-AADC-CCDF2350185EQ34373472-E5C76316-07A8-4BEB-94C6-C721D782D9B6Q34543345-644C45C2-3F19-4CE2-923D-EFDB063E6FCAQ35025478-64BDF10F-4B1E-4506-9707-510C5F256920Q35039240-B8B9E3A9-E7D7-4807-9C24-86A43D9DB630Q35043887-A7737A5E-EE7C-40C1-AD1D-0D5855DCB8DFQ35176487-6E9DC6D3-0F06-4F21-9A47-422B9745E00CQ35202991-0CAF21E2-BC5C-449A-ACC8-15EFF7956196Q35678741-A7FFECCA-358F-4C88-894D-D9DD2E743E6EQ36081391-1BE55809-279E-468B-9386-53E87869690DQ36223024-4BD6132E-4545-45F5-9205-A4038D23CA0FQ36237312-5AA82107-21D5-485B-BEE9-28E2E23D92D7Q36520144-FC8AE143-A922-4713-BD8B-2B49F720BEC6Q37352143-2CF735A0-F04C-4E3E-AE83-E8115463C37BQ37554470-4AB2F342-155E-4ED1-AFB1-31156E3CE3BAQ37594406-BA6334A9-F00A-43D6-8220-8C106A412F51Q37595980-48B771F4-56F8-4179-876E-EA844E54C065Q37694808-D3095FB8-9CE8-49F4-BCD9-F2FAACF540C1Q37780774-913C3FF3-776A-4FAE-AA5F-95704C006B75Q37944937-2E673A9E-5265-4CAB-A2EA-B18FCD77AACEQ38232382-13BD6F8A-800C-4961-BCBD-09192E4F49DAQ38752503-5F40BE7C-DBC5-4E24-B5C4-66DF93E8D6D1Q38797792-B7E6BA3E-3454-4916-993D-D95593FE5BBFQ38870822-6BF6F47A-9FBD-4A37-B8BA-4196266B6E1AQ38959812-B95FA2DF-7D28-4433-9899-49B8BC39A34EQ39031611-09D9F532-AD68-42CA-A5C1-22B0142F0D5BQ39187167-9935E22B-E29F-4AB7-978E-DACE8CD080A3Q40568796-777AF1D2-B783-49BE-B057-512DD4F3F9EBQ41281453-8EAF10B7-409E-4261-8D5F-10F5FFAEEE8FQ41460456-6EBB8075-2D2E-4A29-9A0A-98309F37E596Q41877193-A56588AC-B24B-4A8F-AC53-3F1F081D4939Q42035019-8D7F5F7B-819D-47B9-B576-105147664B70Q42205607-B7323D25-8B7A-4D6C-9852-108EBFF3B2C1Q42373505-27D54B13-596A-4587-875B-E0088E863EDE
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Balazs Hegedus
@ast
Balazs Hegedus
@en
Balazs Hegedus
@es
Balazs Hegedus
@nl
Balazs Hegedus
@sl
type
label
Balazs Hegedus
@ast
Balazs Hegedus
@en
Balazs Hegedus
@es
Balazs Hegedus
@nl
Balazs Hegedus
@sl
prefLabel
Balazs Hegedus
@ast
Balazs Hegedus
@en
Balazs Hegedus
@es
Balazs Hegedus
@nl
Balazs Hegedus
@sl
P1053
B-6076-2008
P106
P1153
6603383823
P31
P3829
P3835
balazs-hegedus2
P496
0000-0002-4341-4153